Clinical Trials Logo

Filter by:
NCT ID: NCT02414100 Withdrawn - Clinical trials for Pancreatic Ductal Adenocarcinoma

Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy

Start date: December 12, 2013
Phase: N/A
Study type: Observational

This pilot research trial studies patient derived cancer cell lines in identifying molecular changes in patients with previously untreated pancreatic cancer and are receiving gemcitabine hydrochloride-based chemotherapy. Cell lines refer to samples taken from the patient's tumor to grow for many months or years in a laboratory, and can therefore be studied scientifically. Studying cell lines in the laboratory may help doctors understand the genetic changes that occur to the tumor during chemotherapy that allows the tumor to resist or grow despite treatment.

NCT ID: NCT02413853 Withdrawn - Clinical trials for Colorectal Adenocarcinoma

Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer

PRIMIER
Start date: November 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well combination chemotherapy and bevacizumab with or without CBP/beta-catenin antagonist PRI-724 (PRI-724) works in treating patients with newly diagnosed colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as leucovorin calcium, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. PRI-724 may help stop the growth of cancer cells by blocking the specific signaling pathway that cancer cells need to grow and spread. It is not yet known whether combination chemotherapy and bevacizumab works better with or without PRI-724 in treating patients with metastatic colorectal cancer.

NCT ID: NCT02412813 Withdrawn - Clinical trials for Total Knee Replacement Revision

LEGION™ Revision Metal Hypersensitivity Study

Start date: January 2016
Phase: N/A
Study type: Interventional

This is a prospective, randomized, multi-center, metal hypersensitivity study comparing OXINIUM and cobalt chrome femoral components in subjects with failed total knee arthroplasty (TKA).

NCT ID: NCT02411877 Withdrawn - Ischemic Stroke Clinical Trials

REperfusion With Cooling in CerebraL Acute IscheMia II

RECCLAIM-II
Start date: February 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether reducing a patient's body temperature (mild hypothermia of 33 degrees Centigrade) will significantly reduce the risk of brain injury (notably reperfusion injury and hemorrhagic conversion) in patients who have suffered a significant interruption of blood flow to an area of brain (occlusion of large proximal cerebral artery) and have undergone successful removal of that interruption (revascularization).This will be achieved by comparing patients who have undergone hypothermia to those who have not.

NCT ID: NCT02409862 Withdrawn - Clinical trials for Socioemotional Aging

Faces: Choices Study

Start date: January 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The neuropeptide oxytocin (OXT), originally known for its role in inducing uterine contractions has been shown to be involved in many of the social capacities that seem to change with age, such as emotion detection and identification, enhanced social memory, empathy, and trust. Thus, age-related changes in the OXT system may underlie differences between young and older adults in socioemotional functioning. Research on the effects of oxytocin in aging is very scarce; therefore, the purpose of this research project is to determine the effects of oxytocin on socioemotional aging. The aim of this research is to examine the behavioral and neural effects of OXT on decisions of trust in social interactions, perceptions of facial trustworthiness, the ability to read faces, and levels of empathy with other people in samples of young and older adults.

NCT ID: NCT02409498 Withdrawn - Clinical trials for Pelvic Organ Prolapse

Use of Pre-Emptive Pudendal Nerve Block for Pelvic Reconstructive Surgery

Start date: October 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effectiveness of perineal pain control via injection of a local anesthetic to numb the pudendal nerve. The medication which is commonly used for this block is called marcaine. This is called a pudendal block it has been used in obstetrical and gynecologic surgeries for several decades. The goal of this study is to reduce the amount of pain medications taken post operatively after pelvic reconstructive surgery. Subjects undergoing pelvic reconstructive surgery will be recruited during the pre-op visit. Subjects will be asked about their pain level in the PACU and also asked to document their pain score days 1 and 2 post op. They will also be asked to keep a medication log for 14 days post op.

NCT ID: NCT02408991 Withdrawn - Lower Limb Ischemia Clinical Trials

Use Art-assist and Neupogen to Treat Chronic Limb Ischemia

Start date: September 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to measure the concentration of cells and proteins in the patient's blood during administration of Nuopogen (Filgrastim), a medication that is FDA approved for stem cell mobilization, in combination with a programmed pneumatic compression device (PPCD) (Art-Assist Device). The Art-Assist Device is an FDA approved device that promotes blood flow in the patient's legs. A patient will be prescribed this device and this drug to help improve the poor circulation in his/her leg. The use of Nuopogen along with the Art-Assist Device has not been approved by the FDA and is considered experimental. This study is not designed to find out how well the Art-Assist Device works, nor how well the drug works in mobilizing stem cells. Instead, it is a study of how well cells lining blood vessels in calf respond to increases in shear stress, and how well the increase in the population of certain cells in the blood stream effect how the new blood vessels will form. It is important for clinical reasons, and for the purposes of this study, that the patient uses the Art-Assist Device as prescribed on a daily basis as discussed with the patient's doctor

NCT ID: NCT02408458 Withdrawn - Ventral Hernia Clinical Trials

Miromatrix Biological Mesh for Ventral Hernia Repair

MIROMESH PM-1
Start date: June 2015
Phase: N/A
Study type: Interventional

This study is being conducted to gather long-term data of the performance of the Miromatrix Biological Mesh.

NCT ID: NCT02408042 Withdrawn - Lymphoma Clinical Trials

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Start date: April 2015
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.

NCT ID: NCT02407184 Withdrawn - Human Microbiome Clinical Trials

Potential Restoration of the Infant Microbiome

PRIME
Start date: April 2015
Phase: N/A
Study type: Interventional

Understanding the microbiome's important role in human health, the investigators wish to determine how the development of the infant microbiome is impacted by delivery mode, comparing natural vaginal birth to scheduled C-sections. Investigators will look at the oral, nasal, skin, vaginal and fecal bacteria of 78 mothers and their infants from birth to age 1.